Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies
- 1 March 2002
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 105 (5), 371-378
- https://doi.org/10.1016/s0049-3848(02)00038-5
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry.Journal of Chromatography B, 2002
- Antithrombotic Effects and Bleeding Time of Thrombin Inhibitors and Warfarin in the RatThrombosis Research, 1999
- New Antithrombotic AgentsChest, 1998
- Prevention of Venous ThromboembolismChest, 1998
- Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic EnzymesThrombosis and Haemostasis, 1998
- A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip ReplacementNew England Journal of Medicine, 1997
- Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trialsActa Radiologica, 1997
- Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393The Lancet, 1996
- Ventilation-perfusion studies in suspected pulmonary embolismAmerican Journal of Roentgenology, 1979
- Roentgen Diagnosis of Venous Thrombosis in the LegArchives of Surgery, 1972